ArticlePLoS pathogens2013
Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.
Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Vaccines for the common cold.The Cochrane database of systematic reviews · 2022Pooled it
- PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze.Nature communications · 2018Trial
- Induction of neutralising antibodies against conserved rhinovirus capsid protein VP4 is dependent on presentation of VP4 peptide immunogens in a virus-like conformation.PLoS pathogens · 2026Article
- The rhinovirus puzzle: Linking virus and host factors to childhood asthma.The Journal of allergy and clinical immunology · 2026Review
- Clinical Significance of Rhinoviruses and Progress Toward Vaccination.Allergy, asthma & immunology research · 2025Review
- Advances in the Treatment of Enterovirus-D68 and Rhinovirus Respiratory Infections.Infectious disease reports · 2025Review
- Antiviral Activity of Rhamnolipids Nano-Micelles Against Rhinoviruses-In Silico Docking, Molecular Dynamic Analysis and In-Vitro Studies.Current issues in molecular biology · 2025Article
- Impact of exposure frequency on disease burden of the common cold - A mathematical modeling perspective.PloS one · 2025Article
- Editorial Note: Cross-Serotype Immunity Induced by Immunization with a Conserved Rhinovirus Capsid Protein.PLoS pathogens · 2024Article
- The Picornaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens.The Journal of infectious diseases · 2023Article
- Identification of Epitopes on Rhinovirus 89 Capsid Proteins Capable of Inducing Neutralizing Antibodies.International journal of molecular sciences · 2022Article
- Trends and Intensity of Rhinovirus Invasions in Kilifi, Coastal Kenya, Over a 12-Year Period, 2007-2018.Open forum infectious diseases · 2021Article
- Article
- Rhinovirus and asthma: Challenges and opportunities.Reviews in medical virology · 2021Review
- Seasonal Coronaviruses and Other Neglected Respiratory Viruses: A Global Perspective and a Local Snapshot.Frontiers in public health · 2021Review
- Human rhinovirus-specific CD8 T cell responses target conserved and unusual epitopes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- ELISA-Based Assay for Studying Major and Minor Group Rhinovirus-Receptor Interactions.Vaccines · 2020Article
- A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro.Scientific reports · 2020Article
- Vaccine strategies to induce broadly protective immunity to rhinoviruses.Human vaccines & immunotherapeutics · 2020Article
- Exacerbation-Prone Asthma.The journal of allergy and clinical immunology. In practice · 2020Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Human rhinovirus (RV) infections are the principle cause of common colds and precipitate asthma and COPD exacerbations. There is currently no RV vaccine, largely due to the existence of ∼150 strains. We aimed to define highly conserved areas of the RV proteome and test their usefulness as candidate antigens for a broadly cross-reactive vaccine, using a mouse infection model. Regions of the VP0 (VP4+VP2) capsid protein were identified as having high homology across RVs. Immunization with a recombinant VP0 combined with a Th1 promoting adjuvant induced systemic, antigen specific, cross-serotype, cellular and humoral immune responses. Similar cross-reactive responses were observed in the lungs of immunized mice after infection with heterologous RV strains. Immunization enhanced the generation of heterosubtypic neutralizing antibodies and lung memory T cells, and caused more rapid virus clearance. Conserved domains of the RV capsid therefore induce cross-reactive immune responses and represent candidates for a subunit RV vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.